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1. Introduction
Phenylpropanolamine hydrochloride belongs to the sympath-
omimetic amine class of drugs and is structurally related to
ephedrine hydrochloride. Its synthesis was first reported in
1910 (1) and the first 1\merican patent was registered in 1939.
The effects of phenylpropanolamine hydrochloride are largely
the result of alpha-adrenergic agonist activity resulting
from both direct stimulation of adrenergic receptors and
release of neuronal norepinephrine. The principal adverse
effect of phenylpropanolamine hydrochloride is d9se-related
hypertension and ventricular arrhythmia has been'described
(2). Phenylpropanolamine hydrochloride is widely used as a
decongestant and it has been used as an anorectic agent for
over 40 years (3). A report in 1939 (4) described its effect
as an hypertensive agent when administered parenterally.
2. Description
2.1 Name. Formula. MJlecular Mass
Phenylpropanolamine hydrochloride. sometimes
referred to as dl-norephedrine can also be named in a
of ways:
(a) a-(1-aminoethyl)benzenemethanol hydrochloride
(b) a-(1-aminoethyl)benzyl alcohol hydrochloride
(c) (~)-2-amino-Phenylpropan-1-o1 hydrochloride
(d) 2-amino-1-phenyl-1-propanol hydrochloride
(e) a-hydroxy-~-aminopropylbenzene hydrochloride
(f) 1-phenyl-2-amino-1-propanol hydrochloride
number
OH ~
0-" 6-C-NHtHCI- I I Jv
H CH3
C9H13NO MM 187.67
2.2 Trade Names
Propadrine. Control, Obestat and Dietac. Numerous
products containing phenylpropanolamine hydrochloride in
combination with other active ingredients are commercially
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available as appetite sup pres ants and cold and influenza
remedies.
2.3 Appearance, Oiour and Colour
The compound is a white crystalline powder with an
odour resembling that of crude benzoic acid.
3. Synthesis
Phenylpropanolamine hydrochloride is prepared by reacting
benzaldehyde with nitroethane in 95% ethanol in the presence
of sodium hydroxide to form a-(1-nitroethyl)benzyl alcohol
and then reducing this nitro-alcohol to the corresponding
amino compound. A stream of hydrogen chloride passed into a
suitable solution of the base yields the hydrochloride (5)~
4. Physical Properties
4.1 Solubili ty
The sample is sonicated for one minute at ambient
temperature.
Solvent
Water
Methanol
Isopropanol
Diethylether
Ethyl acetate
Chloroform
Benzene
Carbon tetrachloride
Acetonitrile
Acetone
Cyclohexane
4\.2 Melting range
mg/ml
~50-<1000
~50-<1000
~10-<33.3
<0.5
<0.5
<0.5
<0.5
<0.5
<0.5
<0.5
<0.5
Solubility
Soluble
Soluble
Sparingly soluble
Practically insoluble
Practically insoluble
Practically insoluble
Practically insoluble
Practically insoluble
Practically insoluble
Practically insoluble
Practically insoluble
Phenylpropanolamine hydrochloride crystals melt at
190-194°C. The free base melts at 101-101.5°C (6).
4.3 Specific Rotation
The specific rotation, [a] ~5, of phenylpropanolamine
hydrochloride in water is +32° (7).
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Crystal Structure
The crystal structure was determined using single
crystals of phenylpropanolamine hydrochloride obtained by
slow evaporation of an aqueous solution at room temperatur~.
The intensity data were collected on an automatic four-circle
diffractometer using Ni-filtered CUKa radiation. Phenylpro-
panolamine hydrochloride has a monoclinic crystal system with
possible space groups of P2
1
(non-centrosymmetric) or P21/m
(centro symmetric). The cel dimensions are a =7.448A,
b =9.461A, c =14.595A, B = 103.4° with each asymmetric unit
containing two molecules (8).
4.5 Dissociation Constant
The pK of phenylpropanolamine hydrochloride deter-
mined potentiomgtrically at 20°C is 9.44 : 0.04 (9).
4.6 Infrared Spectrum
The infrared spectrum of phenylpropanolamine hydrochloride
is shown in Figure 1. It was obtained from a Nujol mull
between KBr plates using a Perkin-Elmer 180 Infrared Spectro-
photometer. Characteristic band assignments are listed
below.
-1
Frequency (cm )
,
3368
3303
2800-2400
1990
1Q23
1598
1581
1508, 1491
1450
1329
1241, 1208
1128,1088,1054
1031
816, 802
747, 703
Assignment
O-H stretching
NH3+ stretching
NH3+
NH +3
NH3+out of plane deformation
c=c aromatic stretching
NH3+out of plane deformation
c=c aromatic stretching
O-H out of plane deformation
NH3+in plane deformation
O-H in plane deformation
C-H in plane deformation,
monosubstituted benzene
c-o stretching
NH3+rocking
C-H out of plane deformation,
monosubstituted benzene
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Infrared spectrum of phenylpropanolamine hydrochloride in Nujol mull.
362 ISADORE KANFER ET AL.
4.7 Differential Scanning_Calorimetry
Phenylpropanolamine hydrochloride was heated from
320 to 5200K at a rate of 200jminute under an atmosphere of
nitrogen in a Perkin-Elmer Model DSC-2 Differential Scanning
Calorimeter. The thermogram is depicted in Figure 2. A
single endotherm was observed with --an onset temperature of
194.5°C which corresponds to the melting point. The heat of
transition (6H melting) calculated in relation to an indium
standard is 168 :!: 6 Jg-1.
4.8 Proton Magnetic Resonance Spectrum
The 60 MHz proton magnetic resonance spectrum of
phenylpropanolamine base was obtained with a Perkin-Elmer
Model R-12 Spectrometer. The spectrum in CDCl3 with
tetramethylsilane (TMS) as the internal standard is depicted
in Figure 3. The integration and multiplicities are consist-
350 '00 8J( 1,50 500
Figure 2. Differential scanning calorimetry curve of
phenylpropanolamine hydrochloride.
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Ant with the proton assignments.
relative to TMS are :
Proton tbmber J(H ) Chemical
assignment of protons ---=- Shift (6)
-CH3 3 9.0 0 .94 D::>ublet
-NH2' -OH 3 - 2.07 Singlet
N-C-H 1 9.0 3 .12 Quintuplet
O-C-H 1 9.0 4.51 D::>ublet
Aromatic 5 - 7.41 Singlet
An inspection of the D20 exchange spectrum shows disappear-
ance of the resonance at 2.07 ppm. This corresponds to
three protons, one hydroxyl proton and two amino protons.
4.9 Ultraviolet Spectrum
The ultraviolet spectra of phenylpropanolamine
hydrochloride in methanol and 0.1 M HCl at a concentration of
1 mg/ml were obtained with a Beckman Acta M VI ultraviolet
spectrophotometer. The spectrum in methanol is depicted in
Figure 4. The spectrum obtained in methanol shows shoulders
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Chemical shifts (6) in ppm
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Figure 4. Ultraviolet spectrum of phenylpropanolamine
hydrochloride in methanol.
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at 267. 248 and 243 nm whilst in 0.1M HCl shoulders occur at
267. 247 and 242 nm.
Solution
Methanol
0 .1 M HCl
4.10 Mass Spectrum
The low resolution mass spectrum of phenylpropanol-
amine hydrochloride is shown in Figure 5. It was obtained
with a Varian MAT CH5-DF mass spectrometer. Direct probe at
80°C into the ion source was used to obtain the mass spectrum
The molecular ion is not observed. The assignments of some
of the major ions formed are :
mle
132
105
91
77
% Ion
Ph-CH=C(CH2)NH2+Ph-C=O+
Ph-CH +
Ph+ 2
17
29
26
100
5. Methods of Analysis
5.1 Elemental Analysis
Theory (%)
Element
C.
H
N
0
Cl
Hydrochloride
57.62
7.47
18.92
7.46
8.52
Base
70.61
9.80
9.15
10.44
5.2 Ultraviolet Spectrophotometric Analysis
',c
Periodate oxidation of phenylpropanolamine hydro-
chloride has been used. The sample to be determined is
placed in a separatory funnel. sodium bicarbonate and sodium
metaperiodate are added and after standing for about 15 min-
utes the solution is extracted with hexane after the addition
of 1M hydrochloric acid. The extract is filtered and the
Absorption
Maxima (nm) e:-
264.0 133.63
258.0 179.04
252.0 145.44
262.8 144.32
257.0 185.04
251.0 148.82
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absorbance determined at 242nm in 1cm cuvettes using hexane
as the reference. The amount of the oxidation product of
phenylpropanolamine hydrochloride is determined by comparison
of the sample absorbance against the absorbance of a Phenyl-
propanolamine Hydrochloride Reference Standard treated in the
same manner (10) . Ether (11) and chloroform (12) have also
been used for the extraction of the derivative. Wallace (13)
used alkaline periodate oxidation to form benzaldehyde which
was subsequently converted to the semicarbazone derivative,
thus enhancing the specificity and sensitivity of the proce-
dure. Phenylpropanolamine hydrochloride has also been
determined after alkaline extraction into an organic solvent
followed by back--extraction under aqueous acidic conditions
(14).
5.3 Colorimetric Analysis.
Phenylpropanolamine hydrochloride can be reacted
with ninhydrin in a citrate buffer at an elevated tempera-
ture and determined colorimetrically at 570nm (15). This
reaction has been applied to the determination of phenylpro-
panolamine hydrochloride in a multi component mixture by an
automated system which, after phase separation, utilizes the
stream splitting technique to divide the chloroform stream
into segments (16). An ion-pair extraction technique using
an acidic dye, bromo thymol blue, has been utilized and the
resulting chloroform extract determined at 420nm (17).
5.4 Spectrofluorimetric Analysis
Phenylpropanolamine hydrochloride has been deter-
mined by measuring its fluorescamine derivative, 4-phenyl-
spiro[furan-2(3H),1'-phthalan]-3,3'-dione at 480nm whilst
exci ting at 398nm (18). The reaction favours a pH of 9 for
optimal reactivity (19).
5.5 Titrimetric Analysis
After extraction of phenylpropanolamine hydrochlor-
ide from an alkaline aqueous solution with chloroform,
shaking with saturated sodium chloride solution and back-
extracting with an excess of sulphuric acid, the excess acid
is titrated with a standard sodium hydroxide solution using
methyl red as indicator (20).
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5.6 Chromatographic Analysis
5.6.1 Column Chromatography
A weakly basic anion exchange resin,
Amberlite IR-45, was found to be suitable for the separation
of phenylpropanolamine hydrochloride from various dosage forms
and yielded a 99.6% recovery of the drug which was then deter-
mined titrimetrically (21). Being a nitrogenous base, the
drug is retained on a sulphonated polystyrene cation exchange
resin. Determination is then effected by measuring the
ultraviolet absorption after elution with hydrochloric acid
(22, 23). Phenylpropanolamine hydrochloride has been deter-
mined by mixing with ammonium hydroxide, the base eluted with
chloroform from a Celite column and the absorbance measured
at 258.5nm (24). Separation of phenylpropanolamine hydro-
chloride from mixtures of drugs in various dosage forms has
been described. The method involves the retention of
phenylpropanolamine on the first of four Celite columns
followed by elution, addition of sodium hydroxide, extraction
of the free base with chloroform and subsequent determination
at 257nm using sulphuric acid as the reference solution (25).
An on-column periodate oxidation of phenylpropanolamine to
benzaldehyde on a weakly basic Celite column has also been
described and the derivative determined at 267nm (26).
5.6.2 Paper Chromatography
A descending paper chromatographic technique
using WhatmanNo. 1 paper has been reported. The solvent
system consisted of a 1:1 mixture of butanol (saturated with
1M hydrochloric acid) and methanol. After spraying with
Dragendorff's reagent, the resulting orange-red spots were
quantitatively determined by densitometry (27).
5.6.3 Thin Layer Chromatography
A number of thin layer chromatographic
systems have been described for phenylpropanolamine hydro-
chloride and these are listed in Table 1.
5.6.4 Gas Chromatography
Gas chromatography has been extensively used
as a method for determining phenylpropanolamine in pharma-
ceutical preparations and, to a lesser extent, for the
determination of the drug in body fluids. The drug has been
chromatographed directly without derivatization and also as
the silyl, pentafluorophenyloxazalidine, acetone, butanone,
trifluoroacetyltrimethylsilyl, heptafluorobutyryl and
TABLE 1
THIN LAYER CHROMATOGRAPHICSYSTEMS FOR PHENYLPROPANOLAMINE
Solvent System
Chloroform layer from a
mixture of chloroform/
acetic acid/methanol/
water (85:20:8:20)
Not reported
Benzene/ethyl
(70:30)
Benzene/ethyl
(30:70)
Hexane/ethyl
(50:50)
Hexane/ethyl
(30:70)
Ethyl acetate/methanol/
formic acid (69:30:1)
acetate
acetate
acetate
acetate
Adsol'eant
Silica Gel G
(F254) (60~)
Silica Gel G
(F254) (60~)
Gelman ITLC
fibre SAF
HPTLC Silica
Gel 60
Detection
Sprayed with 0.3% p-nitroan-
iline plus 5% sodium nitrite,
heated at 70°C for 15 minutes
then sprayed with 20% sodium
carbonate
Sprayed with buffer (pH 9.3),
oversprayed with fluoresc-
amine/acetone solution and
re-sprayed with buffer
p-nitrobenzoyl chloride
applied and heated (100°C)
Dipped into o-phthalaldehyde
solution followed by 20%
polyethylene glycol in
methanol
Rf Reference
Not
reported
28
0.50 19
29
0.79
0.90
0.76
0.90
0.40 30
Solvent System
Heptane/methanol (60:40)
Benzene/methanol (83:17)
Benzene/acetone/methanol/
dioxane (40:40:4:5)
Ethyl acetate/methanol/
water/ammonia (85:10:3:1)
Chloroform/methanol (4:1)
Chloroform/methanol (4:1)
n-butanol/acetic acid/
water (4:1:5)
Adsorbant
HPTLC Silica
Gel 60
Silica Gel
Silica Gel G
Silica Gel G
(HF254 )
DC-cellulose
TABLE 1 (continued)
Detection
Fluorescamine solution
Sprayed with 0.3% ninhydrin
acid, heated at 100°C for
5 minutes, sprayed with 5%
H2SO4' heated with hot air
for 5 minutes, sprayed with
iodoplatinate reagent then
p-nitroaniline reagent,
heavily sprayed with 25%
alcoholic NaOH solution
Iodine vapour
Iodine vapour
Ninhydrin reagent
0.17
0.14
33
Not
reported
34
Rf Reference
0.45 31
0.37
0.28
Not 32
reported
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2.6-dinitro-4-trifluoromethylbenzenesulphonic acid derivat-
ives. The gas chromatographic conditions are listed in Table
2.
5.6.5 High Performance Li9'!:i.<i__Chr()[!\atography
High performance liquid chromatography has
been used for the determination of phenylpropanolamine alone
and in pharmaceutical formulations but relatively little
information has been published on the high performance liquid
chromatographic analysis of phenylpropanolamine in biological
fluids. Table 3 lists the various methods and associated
conditions which have been reported. A technical report
issued by Waters Associates describes the following condit-
ions for the determination of phenylpropanolamine: 0.3m x 4mm
(i.d.) pBondapak C18 column. methanol/water (50:50) including
PIC reagent B-7. detected at 254nm with a retention time of
3.1 minutes for the drug. A similar' technical bulletin
issued by the Du Pont Cbmpany lists the following conditions:
0.25m x 4.6mm (i.d.) Zorbax TMS column. hexanesulphonic acid/
acetic acid/water/methanol (0.1:1 :68.9:30). detected at 254nm
at a flow rate of 2.5 ml/min and retention time of 2.4
minutes.
6. Stability
Phenylpropanolamine hydrochloride is a relatively stable
compound. A solid state mixture of phenylpropanolamine
hydrochloride. phenylephrine hydrochloride and aspirin in the
presence of starch. sugar and talc was stressed at 70°C for
42 days. Phenylpropanolamine hydrochloride was found to be
quite stable under these conditions. showing a loss of about
10% when assayed by a thin layer chromatographic method (28).
A recent study on phenylpropanolamine hydrochloride in a
film-sealed tablet. however. indicated that the molecule is
subject to decomposition in pharmaceutical formulations with
time at normal and elevated temperatures (52). A significant
decrease in phenylpropanolamine hydrochloride concentration
was observed in stressed samples when assayed by the perio-
date oxidation method (11). Stability studies carried out on
phenylpropanolamine hydrochloride in a decongestant syrup
formulation containing sucrose indicated a reduction in
concentration of the drug. Further studies showed decompo-
sition of phenylpropanolamine hydrochloride in the presence
of fructose. dextrose and 5-(hydroxymethyl)-2-furaldehyde.
but not with sorbitol or levulinic acid. It was speculated
that Schiff base formation probably occurred under the test
conditions (59).
TABLE 2
\
GAS CHROMATOGRAPHICSYSTEMS FOR PHENYLPROPANOLAMINE
Dl:"ug Column
Carrier Column
RT(mins ) Detector
Injected Ref
Source Gas Temp( °C) as -
Tablets, 2.0m x 4.0mm (Ld.-) glass He 200 2.80 FID SHyl 35
syrup 0.1% silicone oil (DC- derivative
710) on 60-80 mesh
dimethyldichlorosilane
treated glass beads
Syrup 2.4m x 3.2mm (o.d.) He 180 1.80 FID Phenylpropan- 36
Pyrex glass olamine
2% SE-30 on Chromo-
(.> sorb W (HP)
tj
Plasma 2.0m x 2.0mm (i.d.) N2
190 5.00 FID Pentafluoro- 37
glass phenyloxazol-
1.25% OV-17 on Gas idine deriv-
Chrom Q ative
Tablets 1.8m x 4mmglass He 230 0.85 FID Phenylpropan- 38
3% OV-17 on Gas olamine
Chrom Q
Urine 2.0m x 2.2mmstain- He 230 0.30 Nitrogen Phenylpropan- 39
less steel olamine
3% OV-1 on Gas
Chrom Q
TABLE 2 (continued)
Drug Column
Carrier Column
RT(mins)
Detector Injected Ref
Source Gas Temp (OC) .as -
Tablets, 1 . 8m x 6. 4mm ( L d. ) N2 220 2.40 FID Phenylpropan-
40
capsules, glass olamine
liquids 1% HI-EFF-8BP and 10% hydrochloride
SE52 on Gas Chrom Q
4% HI-EFF-8BP on Gas 220 1.25
Chrom Q
Raw 1.8-2.4m x 3mm(Ld.) Ar 104 9.10 EC Phenylpropan- 41
Material glass olamine
1.15% SE-30 on Gas 13.40 Acetone deriv-
Chrom P ative
(M
123.50....:J Butanone deriv-(M
ative
Raw 1.4m x 4mm(i.d.) He .Prog- 28.00 FID Trifluoroacetyl- 42
Materi.al glass rammed trimethylsilyl
3% Poly A 103 on 70-250 derivative
Gas Chrom Q
Serum 1 .4m x 3. 2mm (o.d.) N2
140 3.70 EC Heptafluoro- 43
stainless steel butyryl deriv-
5% EGS on AW-DMCS ative
Chromosorb W
Raw 1.1m x 2.5mmglass N2
180 2.55 FID Phenylpropan- 44
Material 18.8% Apiezon N on 138 2.77 olamine
Diatoport S 101 3.18
TABLE 2 (continued)
Drug Column Carrier Column
RT(mins)
Detector Injected Ref
Source Gas Temp ( DC) as -
Raw 1.8m x 2mm(i.d.) N2
250 1.38 EC 2,,6-dinitro- 45
Material glass 4-trifluoro-
3% OV-1 on Supelcoport methyl-benzene-
0.9m x 2mm(i.d.) 220 1.38 sulphonic acid
glass derivative
3% SP-2250 on Supel- 230 0.98
coport
Raw 1.2m x 4mm(i.d.) glass N2 185 1.60
FID Phenylpropan- 46
Material 2% SE-30 and 2% olamine hydro-
Carbowax 20M on chloride
Anachrom ASS
Raw 1.8m x2mm glass He Pro- 8.36 Nitrogen Phenylpropan- 47
Material 3% OV-17 on Anachrom grammed olamine
ASS 100-250
Sio- 1.0m x 6mm(o.d.) N2
FID Phenylpropan- 33
logical glass olamine
Material 7.5% Carbowax 20M on 165 4.10
Chromosorb W
2.0% Carbowax 20M on 120 1.10
Chromosorb G
Urine 1.1m x 3mm(i. d.) glass He 170 Not Nitrogen Phenylpropan- 34
12.5% Apiezon L on reported olamine
Chromosorb W impregnat-
ad with 2% Igepal CO 880
Drug
Source
Tablets;
syrup
Syrup
TABLE3
HIGH PERFORMANCE LIQ~:rD__C_HJ~O~'I'OGRAPHICSYSTEMS FOR PHENYLPROPANOLAMINE
Colwnn
0.5m x 2.1mm (i.d.)
Du Pont Zipax sex
0.3m x 4mm (i.d.)
Waters J.lBondapak C18
;st
Tablets, 0.3m x 4mm(i.d.)
capsules, Waters J.lBondapak
liquid phenyl
Tablets,
liquid
Tablets
0.3m x 4mm (i.d.)
Waters J.lBondapak CN
0.25m x 4.6mm (i.d.)
Whatman Partisil-10-
ODS
Mobile Phase Flow rate
(ml/min)
1.0
0.02M (NH4)2HP04
in 36% dioxane/
water
0.05M KH2P04 in
water containing
13% (v/v) methanol
2.0
Water/methanol/acetic
acid (55:44:1) con-
taining 0.005M sodium
heptane sulphonate
13% acetonitrile in
water containing 1.8%
acetic acid
13% acetonitrile in
water containing 1.8%
acetic acid and
0.005M sodium heptane
sulphonate
-3
2.85 x 10 M ethylene-
diamine buffer (pH
7.44)/acetonitrile
(1 : 1 )
2.0
Gradient
elution
3.8
RT(mins)
2.2
3.0
Not
Stated
7.5
8.8
3.3
Detection Ref
Stated
only as
u.v.
48
254nm 49
254nm 50
254nm 51
216.5nm 52
TABLE 3 (continued)
Drug Column Mobile Phase Flow rate RT(mins) Detection RefSource (ml/min) -
Urine 0.3m x 3.9mm (i.d.) Methanol/water/acetic 2.0 8.2 254nm 53
Waters Bondapak C18 acid (45:54:1)
Syrup 0.3m x 3.9mm (i.d.) Methanol/water (60:40) 1.0 7.4 254nm 54
Waters Bondapak with 0.004M sodium
phenyl heptane sulphonate and
Waters Bondapak C18 1% acetic acid 1.0 11.7
Urine 0.25m x 2mm(i.d.) Chloroform/ethyl 1.2 9.9 450nm 55
Lichrosorb SI 100 acetate/ethanol/
and Wakogel LC 5H n-hexane (25:10:1 :50)
Plasma LDC 5 ODS 40% acetonitrile in 1.8 8.2 Fluorescence 56
water containing detection
ammoniumacetate and
acetic acid
Serum, 0.3m x 3.9mm (i.d.) Acetonitrile/water 1.3 4.8 220nm 57
urine Waters Bondapak C18 (25:75) with 0.005M
sodium heptane sul-
phonate and 0.2% 1M
He!
Syrup 0.15m x 4.6mm (i.d.) 0.1M KH2P04 in 10%
1.0 5.4 198nm 58
Spherisorb S5W aqueous ethanol
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Absorption, Disposition and Pharmacokinetics7.
Relatively little information has been reported on the
metabolism of phenylpropanolamine hydrochloride.;. In urine
studies with human subjects it was found that approximately
90% of the drug was excreted in 24 hours, predominantly
unchanged (11, 60, 61). Sinsheimer et at. (60) found only
4% as transformation products, the major biotransformations
being parahydroxylation to 4-hydroxynorephedrine and oxida-
tive deamination of the side chain, resulting in hippuric
acid. Phenylpropanolamine is also metabolised by phenyl-
ethanolamine-N~ethyltransferase to the corresponding N-
methylated metabolite (62, 63). In the rat and rabbit,
80-90% of 14C of small oral doses of [14C]norephedrine is
excreted in the urine within 24 hours, with 1-2% of the dose
being excreted in the faeces. In the rat, 60% occurs as the
unchanged drug 'and 35% as 4-hydroxynorephedrine. Small
amounts of 4-hydroxyhippuric acid and 1,2-dihydroxy-1-phenyl-
propane were also detected. In the rabbit however, 76% is
excreted as deamination products consisting of 31% 1,2-
dihydroxy-1-phenylpropane, 27% 1-hydroxy-2-oxo-1-phenylpro-
pane and 24% benzoic acid (60). In a study with human
subjects under controlled conditions of urinary pH, acidif-
ication of the urine resulted in the excretion of largely
unchanged phenylpropanolamine hydrochloride, whereas basic
urine conditions resulted in reabsorption of the drug with
little influence on metabolsim (64).
The mean elimination half-life of phenylpropanolamine
hydrochloride in man has been reported as 3.9 hours and the
elimination rate constant as 0.18 hr-1 (11). After oral
administration of phenylpropanolamine hydrochloride as an
aqueous solution, absorption is rapid, being completed in
less than 2.5 hours (64). The tissue distribution of the
drug in dogs 2 hours after administration is kidney> lung>
liver> spleen> brain> heart> muscle> plasma> fat>
cerebrospinal fluid (65).
8. Identification and Determination in Biological Fluids
The isolation and quantitative determination of
phenylpropanolamine from serum/plasma and urine has been
accomplished by gas chromatography (34, 37, 39, 43) and high
performance liquid chromatography (53, 55':57). Typical serum
phenylpropanolamine concentrations after a single dose of
25 mg of the hydrochloride sal~ range from about 5-80 ng/ml
over a period of 24 hours (56). In a more recent study using
378 ISADOREKANFERET AL
a 150 mg sustained-release tablet, serum and urine concentra-
tions ranged from about 60-275 ng/ml and 0.02-100 pg/ml
respectively (57). Typical chromatograms depicting the high
performance liquid chromatographic separation of the drug in
serum and urine are shown in Figures 6 and 7 (57).
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Figure 6.
(a) HPLC chromatogram of blank serum extract.
(b) HPLC chromatogram of serum extract
containing phenylpropanolamine (1)
and ephedrine (2).
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Figure 7.
(a) HPLC chromatogram of blank urine extract.
(b) HPLC chromatogram of urine ex~act
containing phenylpropanolamine (1)
and ephedrin~ (2).
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